<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Multiple endocrine neoplasia type 1: Management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Multiple endocrine neoplasia type 1: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Multiple endocrine neoplasia type 1: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Arnold, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Newey, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Snyder, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder classically characterized by predisposition to tumors of the parathyroid glands (which occur in the large majority of patients by age 50 years), anterior pituitary, and pancreatic islet cells  (<a class="graphic graphic_figure graphicRef132582" href="/z/d/graphic/132582.html" rel="external">figure 1</a>). MEN1 also includes a predisposition to gastrinomas in the duodenum, thymic and bronchopulmonary neuroendocrine tumors (NETs), adrenal tumors, angiofibromas, lipomas, and other tumors  (<a class="graphic graphic_figure graphicRef132581" href="/z/d/graphic/132581.html" rel="external">figure 2</a>). The most common types of tumors in MEN1 are generally benign, but malignancy of some thymic, islet cell, and gastrointestinal tract NETs are important causes of mortality in MEN1. Treatment of MEN1 can differ markedly from that of more common sporadic forms of the relevant endocrine tumors, and referral to centers with major experience and multidisciplinary expertise in MEN1 is strongly recommended.</p><p>This topic will review the treatment of MEN1. The classification, genetics, clinical manifestations, and diagnosis are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2037.html" rel="external">"Multiple endocrine neoplasia type 1: Genetics"</a> and  <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PARATHYROID TUMORS</span><span class="headingEndMark"> — </span>Multiple parathyroid tumors causing primary hyperparathyroidism are the most common manifestation of MEN1, with over 90 percent penetrance by age 50 to 70 years  (<a class="graphic graphic_figure graphicRef132582" href="/z/d/graphic/132582.html" rel="external">figure 1</a>) [<a href="#rid1">1-3</a>]. Pathologic hypercellularity of multiple glands is common in these patients and, given sufficient time, perhaps universal. Patients with classical MEN1 are at high risk of recurrent hyperparathyroidism after apparently successful subtotal parathyroidectomy.</p><p class="headingAnchor" id="H3"><span class="h2">Symptomatic disease</span><span class="headingEndMark"> — </span>Once the biochemical diagnosis of primary hyperparathyroidism is confirmed in a patient with known or presumed MEN1, the indications for surgical intervention are similar to those in patients with sporadic primary hyperparathyroidism. These include symptomatic or marked hypercalcemia, nephrolithiasis, and evidence of bone disease, such as diminished bone density or fracture [<a href="#rid4">4</a>]. Bone density of the lumbar spine and hip can improve after parathyroidectomy in patients with hyperparathyroidism associated with MEN1, as it does in patients with sporadic hyperparathyroidism [<a href="#rid5">5</a>] or perhaps to a lesser degree [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management", section on 'Candidates for surgery'</a>.)</p><p>An additional indication for parathyroidectomy in patients with MEN1 is the presence of severe peptic ulcer disease or other symptoms caused by a gastrinoma (the Zollinger-Ellison syndrome) that are difficult to control with medications. Hypercalcemia typically worsens hypergastrinemia, and parathyroidectomy may markedly reduce gastrin secretion in patients with a gastrinoma [<a href="#rid7">7,8</a>]. The typical high success of pharmacologic therapy for hypergastrinemia makes this a rare indication for operation.</p><p>The surgical approach is discussed below. (See <a class="local">'Surgical management'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h2">Asymptomatic disease</span><span class="headingEndMark"> — </span>Surgery or no therapy can be acceptable alternatives for patients with MEN1 who have asymptomatic or minimally symptomatic hyperparathyroidism, as they are for patients with sporadic hyperparathyroidism (see  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management"</a>). Whether early treatment of hyperparathyroidism reduces mortality or morbidity in patients with MEN1 is not known, but many clinicians lean toward surgery in young patients because of their long life expectancy (and years at risk for developing bone disease). In addition, kidney function has been reported to improve after parathyroidectomy in MEN1 patients with hyperparathyroidism and reduced glomerular filtration rate [<a href="#rid9">9</a>]. On the other hand, other clinicians defer surgery as long as possible, in the hope that fewer operations for recurrent hyperparathyroidism (which may be more difficult than the initial surgery) will be needed during the patient's lifetime, and acknowledging that hypoparathyroidism (ie, potentially resulting from extensive parathyroid surgery) may also be associated with considerable morbidity.</p><p>The clinician's threshold for recommending surgery for patients with asymptomatic hyperparathyroidism bears importantly on the decision to screen asymptomatic persons at risk (see  <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis", section on 'Family members in MEN1 kindreds'</a>). Such decisions must also take into account the level of surgical expertise available at one's institution, an important consideration because of the likelihood of recurrent hyperparathyroidism and need for another operation in the future.</p><p>We tend to defer surgery in young MEN1 patients with asymptomatic hyperparathyroidism who lack any specific indications for surgery, such as nephrolithiasis. In such patients, periodic monitoring should be performed for disease progression and development of indications for surgery. (See  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management", section on 'Monitoring'</a>.)</p><p>We do, however, tend to recommend surgery for asymptomatic patients with reduced bone density or declining renal function for the reasons mentioned above and, therefore, find it reasonable to regularly screen individuals with MEN1 for biochemical hyperparathyroidism. (See  <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis", section on 'Monitoring for MEN1-associated tumors'</a>.)</p><p class="headingAnchor" id="H2618398055"><span class="h2">Surgical management</span></p><p class="headingAnchor" id="H5"><span class="h3">Preoperative localization</span><span class="headingEndMark"> — </span>Most patients with MEN1 have multiple parathyroid tumors, so bilateral exploration of previously unoperated patients should be planned, regardless of the outcome of preoperative localization studies, such as ultrasonography, sestamibi imaging, or four-dimensional (4D)-computed tomography (CT). Although such imaging studies may not alter the surgical approach or identify all affected glands, the surgeon may find them to be anatomically helpful and may therefore order them. We do routinely obtain localization studies before <strong>reoperation</strong> in patients with recurrent or persistent disease. (See  <a class="medical medical_review" href="/z/d/html/2069.html" rel="external">"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism"</a>.)</p><p class="headingAnchor" id="H6"><span class="h3">Surgical approach</span><span class="headingEndMark"> — </span>The optimum extent of the parathyroidectomy procedure remains controversial. Some favor a more extensive procedure to reduce the risk of persistent or recurrent disease, while others favor a less extensive procedure to decrease the risk of hypoparathyroidism. </p><p>For patients with MEN1 and indications for initial parathyroidectomy, we favor bilateral neck exploration in an attempt to find all glands. In most cases, we suggest subtotal parathyroidectomy. Subtotal parathyroidectomy involves removal of three and one-half parathyroid glands (or all but one-half gland, if supernumerary glands are found), together with transcervical thymectomy. We view subtotal parathyroidectomy as the preferred approach because it is likely to yield a more sustained duration of normocalcemia than removal of fewer glands, and less likely to cause long-term hypoparathyroidism than complete parathyroidectomy.</p><p>We do not generally advocate lesser surgical approaches, but if they are to be considered in selected patients (eg, averse to more comprehensive surgery), it is important that the potential for persistent or early recurrent disease is fully discussed with the patient. Surgery is repeated if hypercalcemia and specific indications persist or recur [<a href="#rid2">2,10-12</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subtotal parathyroidectomy rather than removal of fewer glands </strong>– Previous studies have indicated that subtotal parathyroidectomy is likely to provide the optimal balance between likelihood of recurrent hyperparathyroidism and permanent hypoparathyroidism [<a href="#rid13">13</a>], and in most circumstances, this is also our favored approach. </p><p></p><p class="bulletIndent1">Patients with classical MEN1 are at high risk of recurrent hyperparathyroidism even after initially successful subtotal parathyroidectomy; in one report, the recurrence rate was 67 percent after eight years [<a href="#rid14">14</a>]. This finding reflects the strong and seemingly inexorable proliferative drive in parathyroid cells in this disorder. </p><p></p><p class="bulletIndent1">In observational studies, recurrent disease is more common among patients who were treated with less than subtotal parathyroidectomy [<a href="#rid2">2,8,15-20</a>]. One report from the National Institutes of Health, for example, found a recurrence rate of greater than 50 percent at 12 years; the rate for long-term remission of hypercalcemia after initial parathyroidectomy was higher after removal of three or more glands compared with removal of two and a half or less (70 versus 34 percent) [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some centers have advocated lesser surgical approaches, particularly in young patients. The rationale for less than subtotal approaches (eg, unilateral clearance of ipsilateral glands) is to achieve a period of eucalcemia, without the risk of hypoparathyroidism, accepting that further surgery will be required at a later stage. However, these lesser approaches are reported to be associated with very high rates of persistent and recurrent hypercalcemia. One study evaluating 99 patients with MEN1 reported persistent hyperparathyroidism in approximately 70 percent of those who had only one or two glands removed at surgery compared with 6 percent in those who had ≥3.5 glands removed (median follow-up approximately 23 months) [<a href="#rid19">19</a>]. Other groups have reported more favorable short- to medium-term outcomes with these lesser approaches (eg, removal of one or two glands) with lower rates of persistent (14 percent) and recurrent hyperparathyroidism (21 percent), although longer-term outcome data are not available [<a href="#rid18">18,20</a>]. Of additional concern regarding an approach that could increase the number of parathyroid operations needed during a patient's lifetime would be a potentially heightened longer-term risk for surgical complications (eg, hypoparathyroidism, recurrent laryngeal nerve damage).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subtotal parathyroidectomy rather than complete parathyroidectomy </strong>–<strong> </strong>Some experts favor a more extensive procedure than subtotal parathyroidectomy to reduce the risk of persistent or recurrent disease. </p><p></p><p class="bulletIndent1">A more aggressive initial surgical approach involves complete parathyroidectomy and placement of a small parathyroid autograft in the muscles of the forearm or neck [<a href="#rid21">21-24</a>]. Recurrent hyperparathyroidism due to growth of the autograft can then be treated by graft removal under local anesthesia. If, however, the autograft does not function, the patient may have the extremely undesirable outcome of long-term or permanent hypoparathyroidism.</p><p></p><p class="bulletIndent1">There are no randomized trials comparing the two approaches. In a review of 18 reports of 2 to 73 patients with MEN1 followed for 4 to 12 years after subtotal parathyroidectomy (three and one-half glands resected) with or without cervical thymectomy, persistent hyperparathyroidism was reported in 0 to 33 percent, recurrent hyperparathyroidism in 0 to 36 percent, and persistent hypoparathyroidism in 0 to 35 percent [<a href="#rid15">15</a>]. In the same review, there were 10 reports of 4 to 36 patients with MEN1 who had complete parathyroidectomy with cervical thymectomy and autologous placement of a small parathyroid autograft. After a mean follow-up of 6 to 10 years, persistent hyperparathyroidism was reported in 0 to 3 percent, recurrent hyperparathyroidism in 0 to 55 percent, and hypoparathyroidism in 0 to 46 percent. In these observational studies, the more aggressive approach was associated with lower rates of persistent hyperparathyroidism but higher rates of hypoparathyroidism.</p><p></p><p class="bulletIndent1">When performed by a surgeon who has extensive experience in either subtotal parathyroidectomy or complete parathyroidectomy, as surgery for MEN1 patients should be, results should be good and complication rates low [<a href="#rid25">25</a>]. Overall, however, we view subtotal parathyroidectomy as the generally preferable approach in large part because of its lesser likelihood of causing long-term hypoparathyroidism [<a href="#rid2">2,12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thymectomy</strong> – Cervically accessible thymectomy during initial parathyroidectomy in MEN1 is generally recommended, acknowledging that high-quality evidence from randomized trials is lacking [<a href="#rid12">12,26-28</a>]. The rationales for thymectomy relate to the substantial frequency with which intrathymic parathyroid tissue is found as a present or future source of pathologic parathyroid hormone (PTH) production [<a href="#rid26">26</a>], and to the risk in MEN1 for developing thymic carcinoid, a rare but often aggressive tumor [<a href="#rid27">27</a>]. Since only part of the thymus is accessible cervically, this measure will not completely neutralize these risks. Still, we think the expected benefit of preventing some thymic carcinoids and lessening the risk of recurrent hyperparathyroidism outweighs the potential risk of this procedure in the hands of an expert surgeon, so we generally favor thymectomy in this setting [<a href="#rid25">25,29</a>].</p><p></p><p class="headingAnchor" id="H4445841"><span class="h2">Medical management</span><span class="headingEndMark"> — </span>Calcimimetic agents (eg, <a class="drug drug_general" data-topicid="8850" href="/z/d/drug information/8850.html" rel="external">cinacalcet</a>) activate the calcium-sensing receptor in the parathyroid gland, thereby inhibiting PTH secretion. Although not typically used in the United States for the treatment of sporadic benign primary hyperparathyroidism, cinacalcet reduces serum calcium in the majority of affected patients. (See  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management", section on 'Severe hypercalcemia'</a>.)</p><p><a class="drug drug_general" data-topicid="8850" href="/z/d/drug information/8850.html" rel="external">Cinacalcet</a> also appears to decrease the serum calcium concentration in patients with primary hyperparathyroidism due to MEN1 [<a href="#rid30">30</a>], although the data are limited. In a case report of a patient with MEN1 and recurrent hyperparathyroidism five years after parathyroidectomy, treatment with cinacalcet reduced serum calcium and PTH levels to normal [<a href="#rid31">31</a>]. During one year of treatment, levels remained normal. Similarly, in a one-year study of MEN1-associated hyperparathyroidism, cinacalcet reduced serum calcium levels (but not PTH) and was generally well tolerated; bone mineral density (BMD) at the spine and femur (no distal radius data) were unchanged, as was urinary calcium excretion [<a href="#rid32">32</a>]. Thus, cinacalcet may be beneficial for patients with MEN1 and recurrent symptomatic primary hyperparathyroidism who are not candidates for or refuse repeated surgical procedures. However, there are no long-term data evaluating the effect of cinacalcet on clinically important outcomes (eg, bone density, fracture, nephrolithiasis, mortality) in patients with MEN1.</p><p class="headingAnchor" id="H7"><span class="h1">PITUITARY ADENOMAS</span><span class="headingEndMark"> — </span>Approximately 15 to 20 percent of patients with MEN1 have clinically apparent pituitary adenomas, or approximately 40 percent if one includes microadenomas detected via systematic screening of asymptomatic individuals [<a href="#rid33">33</a>]. The characteristics of these adenomas in terms of hormonal activity and other features are similar to those in patients with sporadic pituitary adenomas. The most common pituitary adenoma in MEN1 is a lactotroph adenoma, but all other types of adenomas can occur  (<a class="graphic graphic_figure graphicRef132581" href="/z/d/graphic/132581.html" rel="external">figure 2</a>). Multiple pituitary tumors are rarely present in MEN1. (See  <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis"</a>.)</p><p>Individuals with MEN1 who have pituitary adenomas should generally be treated in the same way as patients with sporadic adenomas [<a href="#rid2">2,12</a>]. (See  <a class="medical medical_review" href="/z/d/html/6630.html" rel="external">"Management of hyperprolactinemia"</a> and  <a class="medical medical_review" href="/z/d/html/6631.html" rel="external">"Treatment of gonadotroph and other clinically nonfunctioning adenomas"</a> and  <a class="medical medical_review" href="/z/d/html/118.html" rel="external">"Primary therapy of Cushing disease: Transsphenoidal surgery and pituitary irradiation"</a> and  <a class="medical medical_review" href="/z/d/html/6625.html" rel="external">"Treatment of acromegaly"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">PANCREATIC ISLET CELL/GASTROINTESTINAL TUMORS</span><span class="headingEndMark"> — </span>Because of the efficacy of therapy for hyperparathyroidism and pituitary tumors in patients in MEN1, malignant pancreatic islet cell and gastrointestinal tumors (enteropancreatic tumors) are the primary life-threatening components of the disorder. Endocrine cell tumors at these sites become clinically apparent in approximately one-third of patients with MEN1. However, subclinical involvement is more common; anatomic or intensive biochemical studies reveal evidence of enteropancreatic tumors in up to 80 percent of patients with MEN1  (<a class="graphic graphic_figure graphicRef132582" href="/z/d/graphic/132582.html" rel="external">figure 1</a>).</p><p>The most common cause of symptoms is the Zollinger-Ellison (gastrinoma) syndrome  (<a class="graphic graphic_table graphicRef74208" href="/z/d/graphic/74208.html" rel="external">table 1</a>). Approximately 40 percent of patients with MEN1 have either the Zollinger-Ellison syndrome or asymptomatic elevation in serum gastrin concentrations. Symptomatic insulinomas are also fairly common, but tumors that are symptomatic due to secretion of vasoactive intestinal polypeptide, glucagon, or pancreatic polypeptide are rare. Clinically nonfunctioning pancreatic neuroendocrine tumors (NETs) are now the leading cause of premature mortality in MEN1, and their management remains challenging. Given the complexity of decision-making and specialized skills needed for treating duodenopancreatic endocrine tumors in MEN1, it is strongly recommended that this be done in centers with established multidisciplinary teams experienced in the care of MEN1 patients. </p><p>Surgical treatments are typically recommended for functioning tumors located within the pancreas in the absence of metastatic disease (eg, insulinoma), while surgery for nonfunctioning pancreatic NETs is typically based on size thresholds. Although these vary among centers, all would advocate surgery for nonfunctioning tumors ≥2 cm [<a href="#rid34">34,35</a>]. There are a wide range of treatment options available for patients with metastatic disease including systemic therapies and/or localized treatment approaches as employed for patients with sporadic NETs, although their optimal use has not been established in MEN1 patients. (See  <a class="medical medical_review" href="/z/d/html/90664.html" rel="external">"Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Zollinger-Ellison syndrome</span><span class="headingEndMark"> — </span>Active Zollinger-Ellison syndrome as part of the MEN1 syndrome should be treated primarily by proton pump therapy to limit the clinical manifestations and complications of peptic ulcer disease. The role of duodenal-pancreatic surgery to prevent metastatic disease is uncertain and controversial but could prove beneficial and requires further study.</p><p class="headingAnchor" id="H2290283"><span class="h3">General therapeutic considerations</span><span class="headingEndMark"> — </span>Early attempts to treat the Zollinger-Ellison syndrome surgically in patients with MEN1 involved resection of palpable tumors or partial pancreatectomy, but historically, this approach typically failed to cure the hypersecretion of gastrin [<a href="#rid36">36,37</a>]. The recognition that patients with MEN1 often have small, multifocal tumors in the duodenum, not infrequently accompanied by lymph node metastases [<a href="#rid38">38,39</a>], is consistent with these failures and led to reexamination of the role of surgery. In a controversial area with a dearth of prospective studies to provide guidance, some surgeons are less inclined to operate, while some now regularly operate on MEN1 patients with the Zollinger-Ellison syndrome that persists after correction of hyperparathyroidism or if imaged tumors in the pancreaticoduodenal region exceed a certain size threshold (eg, 2 cm) [<a href="#rid39">39-43</a>]. </p><p>If surgery is undertaken, one recommended approach includes duodenotomy and resection of detectable duodenal wall tumors, often preceded by endoscopic ultrasound (EUS) or accompanied by intraoperative ultrasonography, combined with subtotal/distal pancreatectomy and enucleation of tumors in the pancreatic head [<a href="#rid44">44-46</a>]. Even more aggressive resections, with increased risk of short- and long-term complications, are sometimes performed, subject to modification based upon the individual situation, including complete pancreatoduodenectomy (eg, in the setting of large pancreatic head tumors) [<a href="#rid2">2,12,41,47</a>]. </p><p>Given the impressive efficacy of proton pump blockers in controlling symptoms and the fact that surgery for primary gastrinoma in MEN1 is unlikely to result in cure [<a href="#rid48">48</a>], the primary benefit to be sought from surgery is a decrease in mortality from metastatic gastrinoma. While results of modern surgical approaches seem promising [<a href="#rid43">43,44,46,49-51</a>], longer follow-up studies are needed because the likelihood of developing hepatic metastases and death may be low even in unoperated patients [<a href="#rid39">39,46</a>]. Currently, no definitive evidence exists that surgery decreases the mortality of the disease in MEN1 or the likelihood that clinically important metastases will develop, although nonrandomized evidence suggests that it may [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H2290290"><span class="h3">Pharmacologic treatment</span><span class="headingEndMark"> — </span>Medical therapy for patients with a MEN1-associated gastrinoma is administration of a proton pump inhibitor, such as <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">omeprazole</a> or <a class="drug drug_general" data-topicid="9546" href="/z/d/drug information/9546.html" rel="external">lansoprazole</a> (see  <a class="medical medical_review" href="/z/d/html/2584.html" rel="external">"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)", section on 'Medical management'</a>). When given once or twice daily, these drugs effectively inhibit acid secretion and relieve acid-peptic symptoms in these patients for prolonged periods [<a href="#rid43">43,52</a>]. A nine-year prospective study of the safety and efficacy of omeprazole revealed no tachyphylaxis or important toxicity [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H2290309"><span class="h3">Surgery</span><span class="headingEndMark"> — </span>The question of whether or not to recommend duodenal-pancreatic surgery in patients with MEN1 who have pharmacologically controllable Zollinger-Ellison syndrome and no other clinically evident hormonal excess syndrome or imaged tumors is an especially difficult one. Because clinical outcome data are not definitive, we extensively discuss potential advantages and risks of both options with the patient. While we do not strongly advocate for surgery, we do not discourage a patient who wishes to have surgery for MEN1-associated Zollinger-Ellison syndrome, as long as the individual recognizes that solid proof of improved mortality is lacking and the surgeon is experienced and knowledgeable. Furthermore, if such a patient requires abdominal surgery for another reason (such as insulinoma), it seems appropriate to include duodenotomy in the procedure.</p><p>For patients with pharmacologically controlled Zollinger-Ellison who do not have surgery, we monitor symptoms and perform periodic imaging studies (CT/magnetic resonance imaging [MRI], EUS), with a preference toward minimizing radiation exposure in younger patients. As clinicians who favor pancreaticoduodenal surgery when a tumor exceeds the often used 2 cm size threshold, we generally use published guidance [<a href="#rid4">4</a>] for their timing, but it should be kept in mind that data favoring the use of such specific triggers in improving outcomes (eg, preventing metastases, mortality) are very limited [<a href="#rid39">39,43</a>]. It should also be borne in mind that patients with duodenal gastrinomas may have concomitant nonfunctioning pancreatic tumors, although irrespective of the functional status of the pancreatic lesion, surgery is likely to be beneficial for pancreatic tumors &gt;2 cm [<a href="#rid34">34</a>]. (See <a class="local">'Clinically nonfunctional pancreatic neuroendocrine tumors'</a> below.)</p><p>The best course for patients with hepatic metastases is unclear, and multiple options exist. The considerations are very similar to those with non-MEN1 advanced gastroenteropancreatic endocrine tumors, discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2584.html" rel="external">"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)", section on 'Therapy of metastatic disease'</a> and  <a class="medical medical_review" href="/z/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Insulinoma</span><span class="headingEndMark"> — </span>Approximately 10 percent of patients with MEN1 have an insulinoma  (<a class="graphic graphic_table graphicRef74208" href="/z/d/graphic/74208.html" rel="external">table 1</a>). Approximately 4 to 10 percent of patients with insulinomas have MEN1, and in most, but not all, the MEN1 is known or suspected. Treatment is complicated by the possible presence of multiple insulinomas and/or other pancreatic NETs, the likelihood that preoperative or intraoperative localization techniques may miss small tumors, and the continuing risk for pancreatic tumors after surgery. As a result, some experienced surgeons recommend excision of any tumors found in the head of the pancreas plus a distal subtotal pancreatectomy [<a href="#rid54">54</a>]. This approach differs from that in patients with sporadic insulinomas, who typically have a solitary tumor and in whom localization and local excision alone are usually successful. Functional techniques for preoperatively distinguishing an insulinoma from other pancreatic lesions are under investigation, notably use of 68-Ga-exendin 4 positron emission tomography (PET)/CT imaging, which exploits the high-density expression of the glucagon-like peptide 1 (GLP-1) receptor in benign insulinomas [<a href="#rid12">12,55</a>]. (See  <a class="medical medical_review" href="/z/d/html/2187.html" rel="external">"Insulinoma"</a>.)</p><p class="headingAnchor" id="H548073488"><span class="h2">Clinically nonfunctional pancreatic neuroendocrine tumors</span><span class="headingEndMark"> — </span>In the absence of metastatic disease, the management of nonfunctional pancreatic NETs in MEN1 is controversial [<a href="#rid2">2,12</a>]. The majority of small nonfunctional pancreatic NETs demonstrate indolent growth rates, although occasionally more rapid disease progression occurs. The risk of metastatic disease is reported to be related to increased tumor size, rate of tumor growth, and tumor grade (World Health Organization [WHO] grade ≥2 tumors having a higher risk of metastases). However, accurate noninvasive biomarkers of tumor behavior are currently not available [<a href="#rid35">35</a>]. </p><p>The aims of treatment for nonfunctioning pancreatic endocrine tumors should endeavor to strike a balance between minimizing the risk of metastatic disease while preserving pancreatic tissue, as well as avoiding complications related to pancreatic surgery, acknowledging that patients with MEN1 may develop multiple pancreatic endocrine tumors over their lifetime [<a href="#rid34">34</a>]. Thus, determining the optimal timing of surgery is frequently difficult. Surgery for nonfunctioning pancreatic NETs is typically based on size thresholds:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor size ≥2 cm</strong> – In an emerging consensus (albeit not based on randomized, controlled approaches), many experienced clinicians have been using a tumor size threshold of 2 cm in the decision to surgically resect the lesions [<a href="#rid56">56-58</a>], and corresponding surveillance recommendations have been made [<a href="#rid4">4,59-63</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor size 1 to &lt;2 cm</strong> – Available data offer less guidance for tumors between 1 to &lt;2 cm size, although resection of rapidly growing lesions in this size range is a reasonable approach. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor size &lt;1 cm </strong>– Generally speaking, tumors under 1 cm appear to have a very low risk for substantial growth and metastasis, and avoiding surgery with continued surveillance seems reasonable, given the high morbidity associated with pancreatic surgery. We try to individualize surveillance protocols to minimize lifetime radiation exposure in younger individuals. </p><p></p><p class="bulletIndent1">Clearly, further study of risks, benefits, and alternative approaches would benefit the field [<a href="#rid58">58,64,65</a>]. For example, the role of somatostatin analogues has been investigated in a small number of patients with MEN1 with nonfunctioning pancreatic tumors &lt;2 cm. In an observational study evaluating the effect of the <a class="drug drug_general" data-topicid="10184" href="/z/d/drug information/10184.html" rel="external">lanreotide</a> in 42 MEN1 patients with small nonfunctioning tumors, objective tumor response rates and disease stability improved when compared with an active surveillance group, although such results require caution, and larger controlled studies are required to assess impact of disease progression and survival [<a href="#rid13">13,66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advanced disease</strong> – The management of advanced disease is similar to that used for patients without MEN1 and includes a range of systemic and locoregional approaches. However, the optimal application (and sequencing) of treatment options have not been formally assessed in MEN1 patients. Systemic therapies include somatostatin analogues, targeted molecular therapies (eg, the tyrosine kinase inhibitor <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> and mTOR inhibitor <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>), chemotherapy, and peptide receptor radioligand therapy (eg, with<sup> </sup>177-Lu-dotatate). (See  <a class="medical medical_review" href="/z/d/html/90664.html" rel="external">"Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion"</a>.)</p><p></p><p class="headingAnchor" id="H4073366015"><span class="h1">THYMIC NEUROENDOCRINE TUMORS</span><span class="headingEndMark"> — </span>Thymic neuroendocrine tumors (NETs, thymic carcinoids) occur in 2 to 8 percent of MEN1 patients and, in European populations, occur almost exclusively in males. Symptomatic presentations (eg, anterior chest pain) are typically associated with advanced disease. Surveillance thoracic imaging of asymptomatic individuals (eg, with MRI or CT) may identify earlier stage tumors, although the optimal frequency of such imaging or impact on overall survival has not been established. (See  <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis", section on 'Thymic and bronchopulmonary neuroendocrine tumors'</a> and  <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis", section on 'Monitoring for MEN1-associated tumors'</a>.)</p><p>The treatment of thymic NETs depends on the stage of presentation. When feasible, complete surgical resection is the treatment of choice. For those with advanced disease, additional treatment options include chemotherapy, somatostatin analogs, radiotherapy, mTOR inhibitors, and peptide receptor radioligand therapy, although the evidence base to determine the optimal approach in MEN1 patients is not established. Prophylactic thymectomy at the time of parathyroid surgery is usually recommended, which may reduce (but not entirely exclude) the risk of subsequent thymic NETs [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/16667.html" rel="external">"Thymic neuroendocrine (carcinoid) tumors", section on 'Prognosis and management'</a>.)</p><p class="headingAnchor" id="H859548213"><span class="h1">BRONCHOPULMONARY NEUROENDOCRINE TUMORS</span><span class="headingEndMark"> — </span>Imaging studies indicate that bronchopulmonary NETs occur in 20 to 30 percent of patients with MEN1, although the majority of these patients are asymptomatic with small tumors with indolent growth rates [<a href="#rid67">67</a>]. Larger tumors presenting with clinical symptoms are less frequent. (See  <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis", section on 'Thymic and bronchopulmonary neuroendocrine tumors'</a>.)</p><p>Risk stratification of lesions with imaging (CT for size, growth rates, fludeoxyglucose-positron emission tomography [FDG-PET] for FDG avidity) and/or histologic assessment may help identify lesions with malignant potential. Surgery has been recommended for bronchopulmonary NETs, although the increased detection of small, sometimes multiple and bilateral, slow-growing tumors suggests that surveillance may be appropriate in some settings [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H1973084758"><span class="h1">GASTRIC NEUROENDOCRINE TUMORS</span><span class="headingEndMark"> — </span>Multiple small enterochromaffin-like cell carcinoids (ECLomas; ie, type 2 gastric carcinoids) may occur in MEN1 patients with concurrent hypergastrinemia. Although surgery and somatostatin analogues have been used to treat these tumors, the optimal approach in MEN1 patients remains to be determined. (See  <a class="medical medical_review" href="/z/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors", section on 'Stomach'</a>.)</p><p class="headingAnchor" id="H2944858931"><span class="h1">ADRENAL TUMORS</span><span class="headingEndMark"> — </span>The majority of adrenal tumors occurring in MEN1 are benign, although adrenocortical carcinoma is reported [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis", section on 'Adrenal tumors'</a>.)</p><p>The treatment of functioning adrenal tumors (eg, aldosterone- or cortisol-secreting tumors) does not differ from that of their sporadic counterparts. Otherwise, surgery is reserved for adrenal tumors where malignancy cannot be excluded (eg, large or rapidly growing lesions, or those with indeterminate or concerning imaging characteristics). (See  <a class="medical medical_review" href="/z/d/html/141.html" rel="external">"Treatment of primary aldosteronism"</a> and  <a class="medical medical_review" href="/z/d/html/174.html" rel="external">"Overview of the treatment of Cushing syndrome", section on 'Primary adrenal diseases'</a>.)</p><p class="headingAnchor" id="H439884507"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The long-term mortality of patients with MEN1 is increased compared with the general population or unaffected members of their families [<a href="#rid2">2,12,69</a>]. In a retrospective review of 233 patients with MEN1 treated at the Mayo Clinic, the overall 20-year survival of MEN1 patients was significantly lower than that of an age-, sex-, and geographically matched population (64 versus 81 percent) [<a href="#rid70">70</a>]. Among those in whom a cause of death could be reliably obtained (60 of 69 patients), 28 percent died of causes related to MEN1, most commonly metastatic islet cell tumors. Similarly, in European populations, the mean ages at death for patients with MEN1 was significantly lower than in the average population [<a href="#rid71">71</a>]. Compared with nonaffected patients, those with thymic tumors and duodenopancreatic neuroendocrine or nonfunctioning tumors had a higher risk of death [<a href="#rid72">72</a>]. Because effective treatment is available for hyperparathyroidism and pituitary disease in MEN1, the malignant potential of pancreatic endocrine tumors and carcinoids are the primary life-threatening manifestations of MEN1. These tumors are often present at initial assessment [<a href="#rid27">27,73</a>]. Whether earlier detection through radiographic screening improves mortality remains uncertain [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis", section on 'Monitoring for MEN1-associated tumors'</a>.)</p><p class="headingAnchor" id="H2127658615"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111962.html" rel="external">"Society guideline links: Well-differentiated gastroenteropancreatic neuroendocrine tumors"</a>.)</p><p class="headingAnchor" id="H1181458"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder classically characterized by predisposition to tumors of the parathyroid glands (which occur in the large majority of patients by age 50 years), anterior pituitary, and pancreatic islet cells  (<a class="graphic graphic_figure graphicRef132582" href="/z/d/graphic/132582.html" rel="external">figure 1</a>). MEN1 also includes a predisposition to gastrinomas in the duodenum, thymic and bronchopulmonary neuroendocrine tumors (NETs), adrenal tumors, angiofibromas, lipomas, and other tumors  (<a class="graphic graphic_figure graphicRef132581" href="/z/d/graphic/132581.html" rel="external">figure 2</a>). (See  <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis", section on 'Definition of MEN1'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parathyroid tumors</strong> – The indications for parathyroidectomy in patients with MEN1 are similar to those in patients with sporadic adenomas causing primary hyperparathyroidism and include symptomatic hypercalcemia, nephrolithiasis, and evidence of bone disease, such as diminished bone density or fracture. For asymptomatic or minimally symptomatic hyperparathyroidism, surgery or no therapy can be acceptable alternatives, as they are for patients with sporadic hyperparathyroidism. (See <a class="local">'Symptomatic disease'</a> above and <a class="local">'Asymptomatic disease'</a> above and  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management", section on 'Candidates for surgery'</a>.)</p><p></p><p class="bulletIndent1">For most patients with MEN1 and indications for initial parathyroidectomy, we suggest subtotal (three and one-half gland) parathyroidectomy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We view subtotal parathyroidectomy as the preferred approach because it is likely to yield a more-sustained duration of normocalcemia than removal of fewer glands, and less likely to cause long-term hypoparathyroidism than complete parathyroidectomy. We also suggest cervical thymectomy in this setting (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Surgery should only be performed by surgeons highly experienced in parathyroid surgery. (See <a class="local">'Surgical approach'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pituitary adenomas</strong> – Pituitary adenomas in patients with MEN1 should be treated in the same way as sporadic pituitary adenomas. (See  <a class="medical medical_review" href="/z/d/html/6630.html" rel="external">"Management of hyperprolactinemia"</a> and  <a class="medical medical_review" href="/z/d/html/6625.html" rel="external">"Treatment of acromegaly"</a> and  <a class="medical medical_review" href="/z/d/html/118.html" rel="external">"Primary therapy of Cushing disease: Transsphenoidal surgery and pituitary irradiation"</a> and  <a class="medical medical_review" href="/z/d/html/6631.html" rel="external">"Treatment of gonadotroph and other clinically nonfunctioning adenomas"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Enteropancreatic NETs</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Zollinger-Ellison syndrome</strong> – Active Zollinger-Ellison syndrome as part of the MEN1 syndrome should be treated primarily by proton pump therapy to limit the clinical manifestations and complications of peptic ulcer disease. The role of duodenal-pancreatic surgery to prevent metastatic disease is uncertain and controversial but could prove beneficial and requires further study. (See <a class="local">'Zollinger-Ellison syndrome'</a> above and  <a class="medical medical_review" href="/z/d/html/2584.html" rel="external">"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)", section on 'Medical management'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Insulinoma</strong> – Surgery is indicated for patients with MEN1 and insulinoma. Because patients with MEN1 often have additional pancreatic tumors that may include other insulinomas, local excision of any tumors in the head of the pancreas plus a distal subtotal pancreatectomy is frequently performed. (See <a class="local">'Insulinoma'</a> above and  <a class="medical medical_review" href="/z/d/html/2187.html" rel="external">"Insulinoma"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonfunctioning pancreatic NETs</strong> – Surgery is indicated for patients with MEN1 and nonfunctioning pancreatic NETs ≥2 cm or smaller tumors considered to be at higher risk of progression (eg, rapid growth on serial imaging or higher grade tumors). The majority of small nonfunctioning tumors (&lt;2 cm) run an indolent course with low growth rates such that surveillance is often appropriate. (See <a class="local">'Clinically nonfunctional pancreatic neuroendocrine tumors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Metastatic disease</strong> – The management of metastatic gastroenteropancreatic NETs is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring"</a> and  <a class="medical medical_review" href="/z/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion"</a> and  <a class="medical medical_review" href="/z/d/html/90664.html" rel="external">"Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rizzoli R, Green J 3rd, Marx SJ. Primary hyperparathyroidism in familial multiple endocrine neoplasia type I. Long-term follow-up of serum calcium levels after parathyroidectomy. Am J Med 1985; 78:467.</a></li><li><a class="nounderline abstract_t">Al-Salameh A, Cadiot G, Calender A, et al. Clinical aspects of multiple endocrine neoplasia type 1. Nat Rev Endocrinol 2021; 17:207.</a></li><li><a class="nounderline abstract_t">Romanet P, Mohamed A, Giraud S, et al. UMD-MEN1 Database: An Overview of the 370 MEN1 Variants Present in 1676 Patients From the French Population. J Clin Endocrinol Metab 2019; 104:753.</a></li><li><a class="nounderline abstract_t">Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012; 97:2990.</a></li><li><a class="nounderline abstract_t">Coutinho FL, Lourenço DM Jr, Toledo RA, et al. Bone mineral density analysis in patients with primary hyperparathyroidism associated with multiple endocrine neoplasia type 1 after total parathyroidectomy. Clin Endocrinol (Oxf) 2010; 72:462.</a></li><li><a class="nounderline abstract_t">Silva AM, Vodopivec D, Christakis I, et al. Operative intervention for primary hyperparathyroidism offers greater bone recovery in patients with sporadic disease than in those with multiple endocrine neoplasia type 1-related hyperparathyroidism. Surgery 2017; 161:107.</a></li><li><a class="nounderline abstract_t">Mai HD, Sanowski RA. Regression of duodenal gastrinomas in a patient with multiple endocrine neoplasia type I after parathyroidectomy. Gastrointest Endosc 1992; 38:706.</a></li><li><a class="nounderline abstract_t">Norton JA, Venzon DJ, Berna MJ, et al. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg 2008; 247:501.</a></li><li><a class="nounderline abstract_t">Green P, Zagzag J, Patel D, et al. High prevalence of chronic kidney disease in patients with multiple endocrine neoplasia type 1 and improved kidney function after parathyroidectomy. Surgery 2019; 165:124.</a></li><li><a class="nounderline abstract_t">Carling T, Udelsman R. Parathyroid surgery in familial hyperparathyroid disorders. J Intern Med 2005; 257:27.</a></li><li><a class="nounderline abstract_t">O'Riordain DS, O'Brien T, Grant CS, et al. Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia types 1 and 2. Surgery 1993; 114:1031.</a></li><li><a class="nounderline abstract_t">Brandi ML, Agarwal SK, Perrier ND, et al. Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocr Rev 2021; 42:133.</a></li><li><a class="nounderline abstract_t">Pieterman CRC, Valk GD. Update on the clinical management of multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) 2022; 97:409.</a></li><li><a class="nounderline abstract_t">Burgess JR, David R, Parameswaran V, et al. The outcome of subtotal parathyroidectomy for the treatment of hyperparathyroidism in multiple endocrine neoplasia type 1. Arch Surg 1998; 133:126.</a></li><li><a class="nounderline abstract_t">Tonelli F, Marcucci T, Giudici F, et al. Surgical approach in hereditary hyperparathyroidism. Endocr J 2009; 56:827.</a></li><li><a class="nounderline abstract_t">Stålberg P, Carling T. Familial parathyroid tumors: diagnosis and management. World J Surg 2009; 33:2234.</a></li><li><a class="nounderline abstract_t">Schreinemakers JM, Pieterman CR, Scholten A, et al. The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review. World J Surg 2011; 35:1993.</a></li><li><a class="nounderline abstract_t">Manoharan J, Albers MB, Bollmann C, et al. Single gland excision for MEN1-associated primary hyperparathyroidism. Clin Endocrinol (Oxf) 2020; 92:63.</a></li><li><a class="nounderline abstract_t">Nilubol N, Weinstein LS, Simonds WF, et al. Limited Parathyroidectomy in Multiple Endocrine Neoplasia Type 1-Associated Primary Hyperparathyroidism: A Setup for Failure. Ann Surg Oncol 2016; 23:416.</a></li><li><a class="nounderline abstract_t">Kluijfhout WP, Beninato T, Drake FT, et al. Unilateral Clearance for Primary Hyperparathyroidism in Selected Patients with Multiple Endocrine Neoplasia Type 1. World J Surg 2016; 40:2964.</a></li><li><a class="nounderline abstract_t">Hellman P, Skogseid B, Juhlin C, et al. Findings and long-term results of parathyroid surgery in multiple endocrine neoplasia type 1. World J Surg 1992; 16:718.</a></li><li><a class="nounderline abstract_t">Baumann DS, Wells SA Jr. Parathyroid autotransplantation. Surgery 1993; 113:130.</a></li><li><a class="nounderline abstract_t">Cohen MS, Dilley WG, Wells SA Jr, et al. Long-term functionality of cryopreserved parathyroid autografts: a 13-year prospective analysis. Surgery 2005; 138:1033.</a></li><li><a class="nounderline abstract_t">Tonelli F, Marcucci T, Fratini G, et al. Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1? Ann Surg 2007; 246:1075.</a></li><li><a class="nounderline abstract_t">Nobecourt PF, Zagzag J, Asare EA, Perrier ND. Intraoperative Decision-Making and Technical Aspects of Parathyroidectomy in Young Patients With MEN1 Related Hyperparathyroidism. Front Endocrinol (Lausanne) 2018; 9:618.</a></li><li><a class="nounderline abstract_t">Powell AC, Alexander HR, Pingpank JF, et al. The utility of routine transcervical thymectomy for multiple endocrine neoplasia 1-related hyperparathyroidism. Surgery 2008; 144:878.</a></li><li><a class="nounderline abstract_t">Goudet P, Murat A, Cardot-Bauters C, et al. Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines). World J Surg 2009; 33:1197.</a></li><li><a class="nounderline abstract_t">Pieterman CR, van Hulsteijn LT, den Heijer M, et al. Primary hyperparathyroidism in MEN1 patients: a cohort study with longterm follow-up on preferred surgical procedure and the relation with genotype. Ann Surg 2012; 255:1171.</a></li><li><a class="nounderline abstract_t">de Laat JM, Pieterman CR, van den Broek MF, et al. Natural course and survival of neuroendocrine tumors of thymus and lung in MEN1 patients. J Clin Endocrinol Metab 2014; 99:3325.</a></li><li><a class="nounderline abstract_t">Moyes VJ, Monson JP, Chew SL, Akker SA. Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism. Int J Endocrinol 2010; 2010:906163.</a></li><li><a class="nounderline abstract_t">Falchetti A, Cilotti A, Vaggelli L, et al. A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet. Nat Clin Pract Endocrinol Metab 2008; 4:351.</a></li><li><a class="nounderline abstract_t">Giusti F, Cianferotti L, Gronchi G, et al. Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1). Endocrine 2016; 52:495.</a></li><li><a class="nounderline abstract_t">de Laat JM, Dekkers OM, Pieterman CR, et al. Long-Term Natural Course of Pituitary Tumors in Patients With MEN1: Results From the DutchMEN1 Study Group (DMSG). J Clin Endocrinol Metab 2015; 100:3288.</a></li><li><a class="nounderline abstract_t">Niederle B, Selberherr A, Bartsch DK, et al. Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement. Neuroendocrinology 2021; 111:609.</a></li><li><a class="nounderline abstract_t">Pieterman CRC, Sadowski SM, Maxwell JE, et al. HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: MEN1-related pancreatic NETs: identification of unmet clinical needs and future directives. Endocr Relat Cancer 2020; 27:T9.</a></li><li><a class="nounderline abstract_t">Akerström G, Johansson H, Grama D. Surgical treatment of endocrine pancreatic lesions in MEN-1. Acta Oncol 1991; 30:541.</a></li><li><a class="nounderline abstract_t">Sheppard BC, Norton JA, Doppman JL, et al. Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study. Surgery 1989; 106:1108.</a></li><li><a class="nounderline abstract_t">Pipeleers-Marichal M, Somers G, Willems G, et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med 1990; 322:723.</a></li><li><a class="nounderline abstract_t">Ito T, Igarashi H, Jensen RT. Zollinger-Ellison syndrome: recent advances and controversies. Curr Opin Gastroenterol 2013; 29:650.</a></li><li><a class="nounderline abstract_t">Norton JA, Fraker DL, Alexander HR, et al. Surgery increases survival in patients with gastrinoma. Ann Surg 2006; 244:410.</a></li><li><a class="nounderline abstract_t">Gauger PG, Doherty GM, Broome JT, et al. Completion pancreatectomy and duodenectomy for recurrent MEN-1 pancreaticoduodenal endocrine neoplasms. Surgery 2009; 146:801.</a></li><li><a class="nounderline abstract_t">Doherty GM. Commentary on "Better Survival But Changing Causes of Death in Patients With Multiple Endocrine Neoplasia Type 1". Ann Surg 2015; 261:e149.</a></li><li><a class="nounderline abstract_t">Jensen RT, Norton JA. Treatment of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1: Some Clarity But Continued Controversy. Pancreas 2017; 46:589.</a></li><li><a class="nounderline abstract_t">Thompson NW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med 1998; 243:495.</a></li><li><a class="nounderline abstract_t">Fraker DL, Alexander HR. The surgical approach to endocrine tumors of the pancreas. Semin Gastrointest Dis 1995; 6:102.</a></li><li><a class="nounderline abstract_t">Doherty GM. Multiple endocrine neoplasia type 1. J Surg Oncol 2005; 89:143.</a></li><li><a class="nounderline abstract_t">Tonelli F, Fratini G, Nesi G, et al. Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg 2006; 244:61.</a></li><li><a class="nounderline abstract_t">Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999; 341:635.</a></li><li><a class="nounderline abstract_t">Hausman MS Jr, Thompson NW, Gauger PG, Doherty GM. The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease. Surgery 2004; 136:1205.</a></li><li><a class="nounderline abstract_t">Wamsteker EJ, Gauger PG, Thompson NW, Scheiman JM. EUS detection of pancreatic endocrine tumors in asymptomatic patients with type 1 multiple endocrine neoplasia. Gastrointest Endosc 2003; 58:531.</a></li><li><a class="nounderline abstract_t">Imamura M, Komoto I, Ota S, et al. Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J Gastroenterol 2011; 17:1343.</a></li><li><a class="nounderline abstract_t">Ito T, Lee L, Jensen RT. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother 2016; 17:2191.</a></li><li><a class="nounderline abstract_t">Metz DC, Strader DB, Orbuch M, et al. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther 1993; 7:597.</a></li><li><a class="nounderline abstract_t">Demeure MJ, Klonoff DC, Karam JH, et al. Insulinomas associated with multiple endocrine neoplasia type I: the need for a different surgical approach. Surgery 1991; 110:998.</a></li><li><a class="nounderline abstract_t">Antwi K, Nicolas G, Fani M, et al. 68Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1. J Clin Endocrinol Metab 2019; 104:5843.</a></li><li><a class="nounderline abstract_t">Sadowski SM, Triponez F. Management of pancreatic neuroendocrine tumors in patients with MEN 1. Gland Surg 2015; 4:63.</a></li><li><a class="nounderline abstract_t">Vinault S, Mariet AS, Le Bras M, et al. Metastatic Potential and Survival of Duodenal and Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1: A GTE and AFCE Cohort Study (Groupe d'étude des Tumeurs Endocrines and Association Francophone de Chirurgie Endocrinienne). Ann Surg 2020; 272:1094.</a></li><li><a class="nounderline abstract_t">Sadowski SM, Pieterman CRC, Perrier ND, et al. Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature. Endocr Relat Cancer 2020; 27:R145.</a></li><li><a class="nounderline abstract_t">Nell S, Borel Rinkes IHM, Verkooijen HM, et al. Early and Late Complications After Surgery for MEN1-related Nonfunctioning Pancreatic Neuroendocrine Tumors. Ann Surg 2018; 267:352.</a></li><li><a class="nounderline abstract_t">Kappelle WF, Valk GD, Leenders M, et al. Growth rate of small pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: results from an endoscopic ultrasound based cohort study. Endoscopy 2017; 49:27.</a></li><li><a class="nounderline abstract_t">Pieterman CRC, de Laat JM, Twisk JWR, et al. Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1-Results From the Dutch MEN1 Study Group. J Clin Endocrinol Metab 2017; 102:3795.</a></li><li><a class="nounderline abstract_t">Triponez F, Sadowski SM, Pattou F, et al. Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small ≤2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne &amp; Groupe d'Etude des Tumeurs Endocrines. Ann Surg 2018; 268:158.</a></li><li><a class="nounderline abstract_t">van Treijen MJC, van Beek DJ, van Leeuwaarde RS, et al. Diagnosing Nonfunctional Pancreatic NETs in MEN1: The Evidence Base. J Endocr Soc 2018; 2:1067.</a></li><li><a class="nounderline abstract_t">van Beek DJ, Nell S, Vorselaars WMCM, et al. Complications After Major Surgery for Duodenopancreatic Neuroendocrine Tumors in Patients with MEN1: Results from a Nationwide Cohort. Ann Surg Oncol 2021; 28:4387.</a></li><li><a class="nounderline abstract_t">van Beek DJ, Nell S, Verkooijen HM, et al. Prognosis after surgery for multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors: Functionality matters. Surgery 2021; 169:963.</a></li><li><a class="nounderline abstract_t">Faggiano A, Modica R, Lo Calzo F, et al. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors &lt; 2 Centimeters. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">van den Broek MFM, de Laat JM, van Leeuwaarde RS, et al. The Management of Neuroendocrine Tumors of the Lung in MEN1: Results From the Dutch MEN1 Study Group. J Clin Endocrinol Metab 2021; 106:e1014.</a></li><li><a class="nounderline abstract_t">Gatta-Cherifi B, Chabre O, Murat A, et al. Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database. Eur J Endocrinol 2012; 166:269.</a></li><li><a class="nounderline abstract_t">Ito T, Igarashi H, Uehara H, et al. Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore) 2013; 92:135.</a></li><li><a class="nounderline abstract_t">Dean PG, van Heerden JA, Farley DR, et al. Are patients with multiple endocrine neoplasia type I prone to premature death? World J Surg 2000; 24:1437.</a></li><li><a class="nounderline abstract_t">Geerdink EA, Van der Luijt RB, Lips CJ. Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening? Eur J Endocrinol 2003; 149:577.</a></li><li><a class="nounderline abstract_t">Goudet P, Murat A, Binquet C, et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 2010; 34:249.</a></li><li><a class="nounderline abstract_t">Waldmann J, Fendrich V, Habbe N, et al. Screening of patients with multiple endocrine neoplasia type 1 (MEN-1): a critical analysis of its value. World J Surg 2009; 33:1208.</a></li></ol></div><div id="topicVersionRevision">Topic 2026 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2858157" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Primary hyperparathyroidism in familial multiple endocrine neoplasia type I. Long-term follow-up of serum calcium levels after parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33564173" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical aspects of multiple endocrine neoplasia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30339208" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : UMD-MEN1 Database: An Overview of the 370 MEN1 Variants Present in 1676 Patients From the French Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22723327" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19650788" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Bone mineral density analysis in patients with primary hyperparathyroidism associated with multiple endocrine neoplasia type 1 after total parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27842919" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Operative intervention for primary hyperparathyroidism offers greater bone recovery in patients with sporadic disease than in those with multiple endocrine neoplasia type 1-related hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1361920" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Regression of duodenal gastrinomas in a patient with multiple endocrine neoplasia type I after parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18376196" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30414705" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : High prevalence of chronic kidney disease in patients with multiple endocrine neoplasia type 1 and improved kidney function after parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15606374" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Parathyroid surgery in familial hyperparathyroid disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7903001" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia types 1 and 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33249439" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Multiple Endocrine Neoplasia Type 1: Latest Insights.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35319130" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Update on the clinical management of multiple endocrine neoplasia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9484721" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The outcome of subtotal parathyroidectomy for the treatment of hyperparathyroidism in multiple endocrine neoplasia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19797826" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Surgical approach in hereditary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19184636" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Familial parathyroid tumors: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21713580" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31626728" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Single gland excision for MEN1-associated primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26542588" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Limited Parathyroidectomy in Multiple Endocrine Neoplasia Type 1-Associated Primary Hyperparathyroidism: A Setup for Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27402205" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Unilateral Clearance for Primary Hyperparathyroidism in Selected Patients with Multiple Endocrine Neoplasia Type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1357833" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Findings and long-term results of parathyroid surgery in multiple endocrine neoplasia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8430361" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Parathyroid autotransplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16360388" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Long-term functionality of cryopreserved parathyroid autografts: a 13-year prospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18043113" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30459713" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Intraoperative Decision-Making and Technical Aspects of Parathyroidectomy in Young Patients With MEN1 Related Hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19040992" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The utility of routine transcervical thymectomy for multiple endocrine neoplasia 1-related hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19294466" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22470073" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Primary hyperparathyroidism in MEN1 patients: a cohort study with longterm follow-up on preferred surgical procedure and the relation with genotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24915123" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Natural course and survival of neuroendocrine tumors of thymus and lung in MEN1 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20585352" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18414463" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26224587" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26126205" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Long-Term Natural Course of Pituitary Tumors in Patients With MEN1: Results From the DutchMEN1 Study Group (DMSG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32971521" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32069215" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: MEN1-related pancreatic NETs: identification of unmet clinical needs and future directives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1677254" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Surgical treatment of endocrine pancreatic lesions in MEN-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2573957" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1968616" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24100728" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Zollinger-Ellison syndrome: recent advances and controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16926567" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Surgery increases survival in patients with gastrinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19789041" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Completion pancreatectomy and duodenectomy for recurrent MEN-1 pancreaticoduodenal endocrine neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25775060" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Commentary on "Better Survival But Changing Causes of Death in Patients With Multiple Endocrine Neoplasia Type 1".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28426491" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Treatment of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1: Some Clarity But Continued Controversy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9681848" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7788282" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The surgical approach to endocrine tumors of the pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15719382" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Multiple endocrine neoplasia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16794390" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10460814" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Surgery to cure the Zollinger-Ellison syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15657577" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14520285" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : EUS detection of pancreatic endocrine tumors in asymptomatic patients with type 1 multiple endocrine neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21455335" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27635672" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8161665" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1684067" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Insulinomas associated with multiple endocrine neoplasia type I: the need for a different surgical approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31298706" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : 68Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25713781" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Management of pancreatic neuroendocrine tumors in patients with MEN 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30585820" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Metastatic Potential and Survival of Duodenal and Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1: A GTE and AFCE Cohort Study (Groupe d'étude des Tumeurs Endocrines and Association Francophone de Chirurgie Endocrinienne).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32229700" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27811505" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Early and Late Complications After Surgery for MEN1-related Nonfunctioning Pancreatic Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27975336" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Growth rate of small pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: results from an endoscopic ultrasound based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28938468" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1-Results From the Dutch MEN1 Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28263205" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small≤2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne&amp;Groupe d'Etude des Tumeurs Endocrines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30202829" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Diagnosing Nonfunctional Pancreatic NETs in MEN1: The Evidence Base.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33521900" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Complications After Major Surgery for Duodenopancreatic Neuroendocrine Tumors in Patients with MEN1: Results from a Nationwide Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33220975" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Prognosis after surgery for multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors: Functionality matters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31586182" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors&lt;2 Centimeters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33135721" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The Management of Neuroendocrine Tumors of the Lung in MEN1: Results From the Dutch MEN1 Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22084155" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23645327" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11038219" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Are patients with multiple endocrine neoplasia type I prone to premature death?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14641000" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19949948" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19350320" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Screening of patients with multiple endocrine neoplasia type 1 (MEN-1): a critical analysis of its value.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
